Category: Corporate NewsBy adminAugust 15, 2023 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure regarding the invitation to shareholders for the EGMNextNext post:Disclosure to EGX on EGM minutesRelated PostsRameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024Rameda 4Q23 Earnings ReleaseMarch 20, 2024Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023Rameda Reports its 3Q23 ResultsNovember 14, 2023Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.November 6, 2023Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic productsJune 1, 2023
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023
Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.November 6, 2023
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic productsJune 1, 2023
